Serum Institute of India (SII) CEO Adar Poonawalla chuan Thawhlehni khan Covid-19 laka invenna damdawi, naupangte hman tur chu thla ruk lo awm leh tur chhungin an pe chhuak dawn niin a sawi.
Pune-a vaccine siamtute hian US biotechnology company Novavax-in naupangte tana Covid-19 vaccine an siam chu tual chhungah siam vein a hmingah Covovax tih an vuah.
“Naupang zingah na tak tak kan hmu tam lo va. Vanneihthlak takin naupangte tana buaina tur hi a reh thei tep a. Thla ruk lo awm leh turah hian an tan vaccine kan tichhuak dawn a, a hmang thei tur pawh kum thum chinah kan tihtlakhniam theih kan inbeisei,” tiin Poonawalla hian a sawi niin news agency PTI chuan a tar lang a. A sawina hmun hi an Delhi-a industry conference-ah a ni tih an tar lan bawk.
“Kan Covovax vaccine hi enchhinna kalpui mek a ni a, tun thleng chuan data lawmawm tak tak a lo chhuak a, naupang kum thum chinin an hman theih turin thla ruk chhungin kan tichhuak ang,” a ti.
Serum Institute CEO hian naupangte hnena vaccine lak theih tur chu a pawm zawng tak a nih thu a sawi bawk a. “Ka ngaihdanah chuan i fate kha laktir ngei a tha. Tihchhiat theih a nei lo va, a him a, hna pawh a thawk tha a. Sorkarin a puan hun nghak la, a bak chu la ang che,” a ti.
India-ah hian January 16 atanga invenna pek kalpui mekah kum 18 leh a chung lam chin pek an ni a. Drugs Controller General of India (DCGI)-in hman a phal, Emergency Use Authorisation (EUA) a pek zinga pakhat chauh, Ahmedabad-a Zydus Cadila-in an siam, ZyCoV-D chauh hi kum 18 hnuai lam hman theih tura tih a la ni a, hei pawh hi kum 12 leh c hung lam tan a ni.
Phalna nei tawh mah se pek erawh kalpui a la ni chuang lo.
Hyderabad-a Bharat Biotech International Limited-in an siam, Covaxin pawh DCGI expert panel chuan kum 2-18 tan hman phal a rawt tawh a. Sorkar laipui erawh chuan phalna pe tak tak tur erawh chuan chiang zawka hriat belh leh deuh tura tih a nih thu parliament inkhawmah a lo sawi tawh.
Covaxin hi India ramah chuan puitling chinin an hman pahnih zinga lar tak a ni.